Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Little Green Pharma to Divest WA Production Site in $7.8 Million Sale and Lease-Back Deal
LGP to sell WA production site for $7.8m in a sale-and-lease-back to fund Australian and European expansion; settlement targeted mid-March 2026.
Latest Stories
Cyclopharm Secures NIH Approval for Technegas, Boosting US Expansion
Cyclopharm wins NIH approval for Technegas, secures US purchase order; installation under FSS imminent as funding targets 250-300 US installs by H2 2026.
IDT Australia Reports Operational Improvements with New Leadership Team and Realignment Strategy
IDT Australia (ASX: IDT) reports improving six-month ops under a new leadership team and realignment strategy; revenue up 20% to $8.4m, EBITDA losses narrowed.
Cleo Diagnostics Selects Next-Generation Ella Platform to Deliver Ovarian Cancer Blood Test
Cleo Diagnostics (ASX:COV) selects Bio-Techne's Ella ELISA platform to run its ovarian cancer test, advancing toward FDA 510(k) filing and supply deal.
Botanix Pharmaceuticals Secures A$45 Million Capital Raise to Fund API Purchases and Supply Chain Diversification
Botanix secures A$45m to buy APIs and diversify supply; new shares A$0.06 at 45.5% discount; Sofdra posts Q2 FY26 A$9.1m revenue, 24% QoQ rise.
Rhythm Biosciences Secures Major Distribution Deal for ColoSTAT with 4Cyte Pathology
Rhythm Biosciences (ASX: RHY) has signed a significant non-exclusive distribution agreement with 4Cyte Pathology for its ColoSTAT test.
Emyria Introduces First Empax Centre to Victoria with Expanded Medibank Funding Agreement
Emyria expands Medibank funding to Victoria, unlocking Empax TRD/PTSD care at Avive Mornington Peninsula; nationwide rollout underway.
Entropy Neurodynamics Granted Australian Patent for TRP8803 to Treat Chronic Pain and Psychiatric Conditions
Entropy Neurodynamics (ASX: ENP) granted Australian patent for TRP8803 (IV psilocybin) for chronic pain and neuropsychiatric disorders; protection to 2042.
Paradigm Biopharmaceuticals Publishes Canine Osteoarthritis Study Showing Durable PPS Benefits
Paradigm Biopharmaceuticals (ASX: PAR) reports durable 26-week canine OA PPS benefits in peer-reviewed PLOS One, bolstering translational human OA potential.
TruScreen Validated as Superior Cervical Cancer Screening Tool in Major Chinese Study
TruScreen Group (ASX: TRU) announced strong validation results from a major Chinese study for its cervical cancer screening tool, positioning it for guidelin
Rhythm Biosciences begins ColoSTAT commercial deployment with first physician enrollment
Rhythm Biosciences (ASX: RHY) has initiated the commercial deployment of its ColoSTAT test by enrolling the first physician in its capped Access Program.
EVE Health Group Launches Libbo ED Treatment and Men’s Health Platform
EVE Health (ASX: EVE) launches Libbo ED treatment and men’s health platform, unveiling an end-to-end digital pathway for nationwide access and scalable revenue.